Removing Cancer’s Veil: TruSight Tumor 170 Gene Panel

November 7, 2016

Introduction to TruSight® Tumor 170, a new enrichment-based cancer research assay that interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants. With minimal nucleic acid input requirements, the panel will allow researchers to evaluate formalin-fixed, paraffin embedded (FFPE) samples that were previously difficult to analyze. Hear from experts about the value this assay can bring to the research community. For Research Use Only. Not for use in diagnostic procedures.

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015.

Subscribe to the Illumina video channel 

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos

Share this article on